Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.

Basolo A, Burkholder J, Osgood K, Graham A, Bundrick S, Frankl J, Piaggi P, Thearle MS, Krakoff J

Metabolism: clinical and experimental26 Mar 2018Cited by 36 (Europe PMC)

PMID29596853PMCIDPMC6062468DOI10.1016/j.metabol.2018.03.017PepBankPUB-29596853

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, exenatide reduced early absolute energy intake more than placebo.
In plain wordsIn people with obesity without diabetes, exenatide reduced early food intake more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAbsolute energy intake
Study
n = 80
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Ad libitum energy intake change
−1016.1 kcal/day
exenatide
Ad libitum energy intake change
−245.1 kcal/day
placebo
Between-group difference
−624.8 kcal/day
exenatide vs placebo
Source sentences
Summary
In the exenatide group, ad libitum absolute energy intake decreased by 1016.1 ± 724.5 kcal/day (95% CI: -1250.9 to -781.2) versus a 245.1 ± 710.5 kcal/day (95% CI: -475.4 to -14.7) decrease in placebo (Δ = -624.8 Kcal/day, p < 0.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685301
02HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, exenatide reduced energy intake relative to weight-maintaining needs more than placebo.
In plain wordsIn people with obesity without diabetes, exenatide reduced food intake relative to maintenance needs more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseEnergy intake relative to weight-maintaining needs
Study
n = 80
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Energy intake relative to WMEN change
−366.8 kcal/day
exenatide
Energy intake relative to WMEN change
−8 kcal/day
placebo
Between-group difference
−382.3 kcal/day
exenatide vs placebo
Source sentences
Summary
whereas the reduction in ad libitum caloric intake relative to WMEN was a more modest 366.8 ± 752.1 kcal/day (95% CI: -614.0 to -119.6) decrease compared to 8.0 ± 860.1 kcal/day (95% CI: -286.8 to 270.8) reduction in placebo (Δ = -382.3 Kcal/day, p = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685302
03HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, exenatide-associated intake reduction was uniform across macronutrient groups.
In plain wordsIn people with obesity without diabetes, exenatide reduced intake uniformly across nutrient groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIntake reduction across macronutrient groups
Study
n = 80
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
The decrease was uniform across all macronutrients groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In the exenatide group, ad libitum absolute energy intake decreased by 1016.1 ± 724.5 kcal/day (95% CI: -1250.9 to -781.2) versus a 245.1 ± 710.5 kcal/day (95% CI: -475.4 to -14.7) decrease in placebo (Δ = -624.8 Kcal/day, p < 0.0001)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685303
04HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, early energy expenditure did not differ between exenatide and placebo.
In plain wordsIn people with obesity without diabetes, early energy use did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEarly 24-hour energy expenditure
Study
n = 80
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
No differences in 24hEE or substrate oxidation rates were found.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685304
05HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, substrate oxidation rates did not differ between exenatide and placebo.
In plain wordsIn people with obesity without diabetes, nutrient burning rates did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSubstrate oxidation rates
Study
n = 80
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
No differences in 24hEE or substrate oxidation rates were found.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685305
06HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, exenatide produced a greater rate of weight decline than placebo over 5 weeks.
In plain wordsIn people with obesity without diabetes, weight decreased faster with exenatide than placebo over 5 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight decline rate over 5 weeks
Study
n = 80
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneous · 5 weeksAs given in this study (human).
Measurements
Weight change slope
−0.039 kg/week
exenatide group over 5 weeks
Source sentences
Summary
In the exenatide group, body weight decreased more over the 5 weeks (β = -0.039 kg/week, p = 0.02) and was lower compared to placebo at the end of fifth week (-1.48 ± 0.77 kg; 95% CI: -3.02 to 0.05, p = 0.06).
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685306
07HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, weight was numerically lower with exenatide than placebo at the fifth week, without statistical significance.
In plain wordsIn people with obesity without diabetes, weight was numerically lower with exenatide than placebo at 5 weeks, without a significant difference.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWeight difference at fifth week
Study
n = 80
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneous · 5 weeksAs given in this study (human).
Measurements
Weight difference versus placebo
−1.48 kg
end of fifth week, exenatide minus placebo
Source sentences
Summary
In the exenatide group, body weight decreased more over the 5 weeks (β = -0.039 kg/week, p = 0.02) and was lower compared to placebo at the end of fifth week (-1.48 ± 0.77 kg; 95% CI: -3.02 to 0.05, p = 0.06).
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685307
08HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, energy intake did not differ between exenatide and placebo at 24 weeks.
In plain wordsIn people with obesity without diabetes, food intake did not differ between exenatide and placebo at 24 weeks.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEnergy intake at 24 weeks
Study
n = 80
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
At the 24-week follow up, there was no difference in energy intake between exenatide group and placebo group and the treatment group decreased 24-h EE more compared to placebo (β = -160.6 Kcal/day, 95% CI: -307.6 to 13.6, p = 0.03) compared to their pre-randomization measurement.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685308
09HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, exenatide decreased unadjusted energy expenditure more than placebo at 24 weeks relative to baseline.
In plain wordsIn people with obesity without diabetes, unadjusted energy use fell more with exenatide than placebo at 24 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUnadjusted energy expenditure at 24 weeks
Study
n = 80
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
24-h energy expenditure change versus placebo
−160.6 Kcal/day
24 weeks, unadjusted, versus pre-randomization
Source sentences
Summary
At the 24-week follow up, there was no difference in energy intake between exenatide group and placebo group and the treatment group decreased 24-h EE more compared to placebo (β = -160.6 Kcal/day, 95% CI: -307.6 to 13.6, p = 0.03) compared to their pre-randomization measurement.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685309
10HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, the exenatide-placebo energy expenditure difference disappeared after adjustment for fat and fat-free mass changes.
In plain wordsIn people with obesity without diabetes, energy use did not differ between exenatide and placebo after adjustment for body composition changes.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody-composition-adjusted energy expenditure
Study
n = 80
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Adjusted 24-h energy expenditure change
−87 kcal/day
24 weeks, adjusted for FM and FFM
Source sentences
Summary
However, this reduction was not present after adjustment for changes in FM and FFM (β = -87 kcal/day, p = 0.14).
2 context sentences(design, population, supporting numbers)
Summary · context
At the 24-week follow up, there was no difference in energy intake between exenatide group and placebo group and the treatment group decreased 24-h EE more compared to placebo (β = -160.6 Kcal/day, 95% CI: -307.6 to 13.6, p = 0.03) compared to their pre-randomization measurement.
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685310
11HumanRandomized controlled trialEfficacy outcome
In non-diabetic volunteers with obesity, weight did not differ significantly between exenatide and placebo over 24 weeks.
In plain wordsIn people with obesity without diabetes, weight did not differ significantly between exenatide and placebo over 24 weeks.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWeight difference at 24 weeks
Study
n = 80
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 μg twice daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Body weight difference versus placebo
−1.72 kg
24 weeks, exenatide versus placebo
Source sentences
Summary
No difference was observed in body weight (Δ = -1.72 kg, 95% CI: -5.77 to 2.30, p = 0.39) in exenatide versus placebo over 24 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4 ± 8.7 y, body fat by DXA: 44.2 ± 7.8%) to subcutaneous exenatide 10 μg twice daily or placebo.
Report a problemFND-2959685311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00856609

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)n = 1503 Mar 2009 to 19 Sept 2016

Weight Loss · Obesity

Trial page ClinicalTrials.govUpdated 4 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.